Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

製品コードS1098 別名:PF-01367338

Rucaparib (AG-014699) phosphate化学構造

CAS No. 459868-92-9

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 24200
JPY 21900
JPY 36800
JPY 113200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(103)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
特性 The first PARP inhibitor used in clinical trials combined with temozolomide.
ターゲット
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 MYjGeY5kfGmxbjDBd5NigQ>? M{HpWFAvOS9zL{WwNE8yODByIH7N NUHGd2EzcW6qaXLpeJMhWEGUUDDhZ5Rqfmm2eTDheEB{fGG{dHnu[{Bkd26lZYLueJJifGmxbjDv[kA2ODBibl2= Ml;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
BT474 M1;GdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLZXodYPTByIH7N NFq1TJgyOOLCk{G1xsBl Mn7jdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> M1jWSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
SKBR3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X5WlUxOCCwTR?= M{PydlEx6oDVMUZCpIQ> M3jtd5Jm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> NGLMfXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
AU565 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XkfFUxOCCwTR?= NY\jUWVrOTEkgKOxOeKh\A>? M{SxWpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> NFmwUpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyPFQ2PSd-MkWxNlg1PTV:L3G+
EFM192A M1fJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK0OVAxKG6P M3rXSVEx6oDVMUZCpIQ> NXHMZpJ[emWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? M333fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
MDA-MB-231 NFXhU|VHfW6ldHnvckBCe3OjeR?= M37Dc|ExNzJyL{SwJO69VQ>? MVuyOEBp NGTTdodqdmO{ZXHz[ZMheC2DS2SgcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWq3fWNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlAyPTJpPkK0OFIxOTV{PD;hQi=>
MDA-MB-231 Ml;nR4VtdCCYaXHibYxqfHliQYPzZZk> M{DxZlAvOS12MDFOwG0> NF3PemgzPCCq NGD4fpBKSzVy4pEJQgKBkTF5Lke3xsDPxE1? NVXSfG8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlAyPTJpPkK0OFIxOTV{PD;hQi=>
MDA-MB-231 MX7BdI9xfG:|aYOgRZN{[Xl? MlnUNVAwOjBxNECg{txO MkDzNlQhcA>? MnLQbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M3O0d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKwNVUzLz5{NESyNFE2OjxxYU6=
MDA-MB-231 NYTWNoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;QNVAwOjBxNECg{txO MlT4NlQhcA>? Mn76Zoxw[2u|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hcW5iR{KvUUBxcGG|ZR?= NY\OTpZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlAyPTJpPkK0OFIxOTV{PD;hQi=>
H460 NW\pZo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnJelI1ODBibl2= M{\BNlI1yqCq Mmm0bY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm= NUHvSmlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVE3OTFpPkK0OFEyPjFzPD;hQi=>
A549  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17GZ|QxOCCwTR?= NVPQS40yOjUEoHi= M2rCfolv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzMU[xNUc,OjR2MUG2NVE9N2F-
DT40 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJzIH7N MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3NkixN{c,OjR|NU[4NVM9N2F-
DU145 M4ThVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXmTWM2OD1zODDuUS=> MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
COLO704 M3rMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrpeWh7UUN3ME2yMlUzKMLzIECuOlch|ryP MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVMANAb NVLnUmhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3aPY1KSzVyPUKuOVghyrFiMD6zPEDPxE1? MorXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV177 NEnHfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;PNHFKSzVyPUKuO|ghyrFiMD63NUDPxE1? M3;3O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OAW28 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLITWM2OD1|Lk[xJOKyKDBwMkig{txO M1jxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVSAHO Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3hTGpKSzVyPUOuOlQhyrFiMD6zN{DPxE1? MmHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVKATE NVnlZldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwNkSgxtEhOS55OTFOwG0> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCAR3 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNwN{SgxtEhOC52MDFOwG0> NYP4W2lJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
PEO14 NW\sbFc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTsTWM2OD1|Lki0JOKyKDBwN{[g{txO M3jjW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
A2780 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwOUSgxtEhOC5{NTFOwG0> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVTOKO NW\NOlZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrHeXFTUUN3ME20MlE1KMLzIEGuOVMh|ryP MmniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
KURAMOCHIb NHzBZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\s[VdKSzVyPUSuN|QhyrFiMD6yPUDPxE1? NGDCbIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
TOV21G Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTVwMEegxtEhOS5|MDFOwG0> NIDtN3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVISE NXzVW3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTVwNkigxtEhOC5{MzFOwG0> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KK M3Xi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTZwMUWgxtEhOS52MjFOwG0> NUTWbIFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
RMUGS NEWy[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjGN2pKSzVyPUeuNFMhyrFiMT64N{DPxE1? MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
PEO6 NGrC[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nRdmlEPTB;Nz6wOkDDuSByLke0JO69VQ>? NXnWZYJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OVCA429 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnK[2RKSzVyPUiuNlkhyrFiMT62OEDPxE1? NIftUm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV167 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfWO3JKSzVyPUiuN|MhyrFiMT6xPEDPxE1? M{HleFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
RMG1 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrVN2dMUUN3ME25MlMzKMLzIEKuN|Yh|ryP M1jhbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCAR5 NWrqfVRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTlwNUCgxtEhOi53OTFOwG0> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
EFO21 NWO4XoVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0e2lEPTB;OT65NkDDuSBzLki3JO69VQ>? MkDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
ES2 NWrDfo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFyLkGyJOKyKDFwMkOg{txO MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
Tyk-nu M33VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e4dWlEPTB;MUCuNlAhyrFiMT6xNkDPxE1? MoLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
CAOV3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXkRVBKSzVyPUGwMlM4KMLzIECuPFch|ryP Ml7UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OV207 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjpSJpKSzVyPUGyMlI4KMLzIECuN|Ih|ryP NGf3PJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
HEY MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zhSWlEPTB;MUOuNFEhyrFiMD63OUDPxE1? Mm\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
DOV13 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHywOmJKSzVyPkG1JO69VQ>? NGLldpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
EFO27 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRjF3IN88US=> M{fpRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
HEY C2 NGDiNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRjF3IN88US=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
KOC-7cc MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvjXWhLUUN3ME6xOUDPxE1? M{m0TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
MCASb NVX0Xm16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\Fe4tPUUN3ME6xOUDPxE1? M{TNVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OAW42 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DYW2lEPTB-MUWg{txO NUTubmt5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OV2008 NVP2W4NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrrU5hZUUN3ME6xOUDPxE1? M3LJWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV90 NHvEVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HQ[GlEPTB-MUWg{txO MnzRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVCA420b MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;VTWM2OD5zNTFOwG0> MnHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVCA432 NVfGXW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPVTWM2OD5zNTFOwG0> NIXrXJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
PEA2 NILFNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRjF3IN88US=> NILsb2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
SKOV3 NEPq[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TVUmlEPTB-MUWg{txO MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
TOV112D M4\DSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPZNE0{KM7:TR?= NHrie4FKSzVyPkG1JO69VQ>? NEDUUXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
C4-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4riOlAuOyEQvF2= M1vjXFE1KGR? NFfndoFFVVOR Mknw[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? M175cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
PC3 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDTNE0{KM7:TR?= NFO4WpQyPCCm NWWxb3VvTE2VTx?= NVOxd5k2\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= MoSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
DU145 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWwMVMh|ryP NFH3b5YyPCCm NFHaXFJFVVOR MlPh[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MmnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ|NU[1NlQ1RC:jPh?=
VCaP  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jzT|AuOyEQvF2= MWqxOEBl MWLEUXNQ NFjsZoxl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
LNCaP  NILhZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTxWWt4OC1|IN88US=> MmnnNVQh\A>? NWn5ZlB[TE2VTx?= NGLGdZRl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
MDA-MB-468 NX7TVY85S2WubDDWbYFjcWyrdImgRZN{[Xl? M1zk[mlEPTB;OT63JO69VQ>? M3PVTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nke4NVYyLz5{Mk[3PFE3OTxxYU6=
MDA-MB-231 M4PXOGNmdGxiVnnhZoltcXS7IFHzd4F6 M4rFbWlEPTB;MUOg{txO NH\SXJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O|gyPjF:L3G+
Cal-51 NX3iPY9LS2WubDDWbYFjcWyrdImgRZN{[Xl? MoTMTWM2OD16Lk[g{txO NFzM[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O|gyPjF:L3G+
LoVo MUTGeY5kfGmxbjDhd5NigQ>? NF7UfIM{OCCvaX7z MWjJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHWvYX6gUI9XdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJBwdHlqQVTQLU1zcWKxc3WgdI9tgW2ncnn6ZZRqd25iZn;yJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC5yMES2PUDPxE1w Mln0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MX1 NYroXYVIS3m2b4TvfIlkcXS7IHHzd4F6 M{D5PGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GxMYRm\mmlaXXueEBpfW2jbjDNXFEh[2WubIOsJGVEPTBiPTCwMlAxPTNizszNMi=> M3;LW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
Rosetta2 (DE3) NUfnc|hrTnWwY4Tpc44h[XO|YYm= Mme5TY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKD[6aHnzMZRi\2enZDDBVnRFPiBqOEezJJRwKDFzNkGpJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKFKxc3X0eIEzKCiGRUOpJINmdGy|IIXzbY5oKE6DRDugZZMhe3Wkc4TyZZRmKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFE1KM7:TT6= M3j5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|cxLz5{NEmwNFc4ODxxYU6=
Rosetta2 (DE3) MXfGeY5kfGmxbjDhd5NigQ>? MVfJcohq[mm2aX;uJI9nKGi3bXHuJFZ5cGm|LYTh[4dm\CCDUmTEOUApOTB|MDD0c{AyOzF5KTDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBTd3OndIThNkApTEV|KTDj[YxteyC3c3nu[{BPSURtIHHzJJN2[nO2cnH0[UBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCyOUDPxE1w M3jDO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|cxLz5{NEmwNFc4ODxxYU6=
LoVo M3fZXGN6fG:2b4jpZ4l1gSCjc4PhfS=> MnLrNE41KHWP NGPZWoY2KGSjeYO= M2f5XXBwfGWwdHnheIlwdiCxZjD0[Y1wgm:ub33p[IUucW6mdXPl[EBkgXSxdH;4bYNqfHliaX6gbJVu[W5iTH;Wc{Bk\WyuczDhd5Nme3OnZDDhd{B1\W2xen;sc41q\GViR1m1NEBifCByLkSgeW0h[W[2ZYKgOUBl[Xm|IHL5JGNmdGy2aYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjF2NDFOwG0v NHKxbJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
Capan1 MoXZR5l1d3SxeHnjbZR6KGG|c3H5 M1vjSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GyMYRm\mmlaXXueEBpfW2jbjDDZZBidjFiY3XscJMtKEWFNUCgQUAxNjZyOTFOwG0v MmnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MDA-MB-436 Mn;sRY51cWOjbnPldkBie3OjeR?= MXG5OkBpenN? M{XVVWFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCVmNCOS2mZX\pZ4lmdnRiTVTBMW1DNTR|NjDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOyEQvF2u NF;jPXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0Nlg3QCd-Mk[zOFI5Pjh:L3G+
OVCAR3 M3OxOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoCxNlQhcHK| Mn31RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCRVlPBVlMh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEOuN|Eh|ryPLh?= Ml;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NU[xNFYoRjJ7NEW2NVA3RC:jPh?=
MRC5 NV7Pb5NoS3m2b4TvfIlkcXS7IHHzd4F6 NHzCRpdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{NCCHQ{WwJF0hQC53MzFOwG0v NFLKfYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MCF7 NUXKVWNUSW62aXPhcoNmeiCjc4PhfS=> MXm5OkBpenN? MWPBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDDR|UxKD1iMUmuOFch|ryPLh?= NV7Bb4lNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOFI5PjhpPkK2N|QzQDZ6PD;hQi=>
A673 M2G2VJFJXFNiYYPzZZk> M2S5SJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NXS5WXhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 NFrHfZZyUFSVIHHzd4F6 MmjldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> NGHjc5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 MlnCdWhVWyCjc4PhfS=> MkXUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> NFLNVVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NWn2NVdTeUiWUzDhd5NigQ>? NWHUR256eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NVL1bJpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 NYjjbJN1eUiWUzDhd5NigQ>? NXLTflRIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? NHPMO3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

24085845 27960087
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

23565244 27515310 30589644
体内試験 Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
細胞試験: [4]
- 合併
  • 細胞株: D425Med, D283Med and D384Med cells
  • 濃度: 0.4 μM
  • 反応時間: 3 or 5 days
  • 実験の流れ: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (参考用のみ)
動物試験:[4]
- 合併
  • 動物モデル: CD-1 nude mice bearing established D283Med xenografts
  • 投薬量: 1 mg/kg
  • 投与方法: One or four daily by i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS No. 459868-92-9
Storage powder
in solvent
別名 PF-01367338
Smiles CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04539327 Recruiting Drug: Rucaparib Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Grupo Español de Investigación en Cáncer de Ovario|Clovis Oncology Inc. July 29 2020 --
NCT04179396 Active not recruiting Drug: Rucaparib|Drug: Enzalutamide|Drug: Abiraterone Metastatic Castration Resistant Prostate Cancer Clovis Oncology Inc. December 5 2019 Phase 1
NCT04171700 Recruiting Drug: Rucaparib Solid Tumor Clovis Oncology Inc. November 21 2019 Phase 2
NCT03824704 Terminated Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine August 23 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Rucaparib (AG-014699) phosphateを買う | Rucaparib (AG-014699) phosphate ic50 | Rucaparib (AG-014699) phosphate供給者 | Rucaparib (AG-014699) phosphateを購入する | Rucaparib (AG-014699) phosphate費用 | Rucaparib (AG-014699) phosphate生産者 | オーダーRucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate化学構造 | Rucaparib (AG-014699) phosphate分子量 | Rucaparib (AG-014699) phosphate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID